City Therapeutics, Inc.于2023年7月17日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司,开发下一代RNAi疗法,旨在抑制疾病相关蛋白的表达,为有需要的患者提供有意义且持久的治疗获益。其管线聚焦于血栓栓塞性疾病、Stargardt病1型和慢性病贫血等重大未满足医疗需求。
10-22 12:00
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities